No.24-14

March 6, 2024
Eisai Co., Ltd.

EISAI INVESTS IN C2N TO SUPPORT SIMPLIFYING THE DIAGNOSIS OF EARLYALZHEIMER’S DISEASE TO BETTER SERVE PATIENTSEisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its U.S. subsidiary
Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC (Headquarters: St. Louis,Missouri, the United States “C2N”) to support C2N’s efforts to expand the availability, accessibility,affordability and utilization of blood-based tests for the diagnosis of Alzheimer’s disease (AD) in the U.S.
This investment is in addition to the collaboration with C2N announced in August 2022 regarding the useof blood-based assays in the diagnosis of people living with dementia in clinical practice in the U.S.
The presence of amyloid β (Aβ), a component of AD pathology, is currently confirmed using advanced
diagnostic techniques such as positron emission tomography (PET) or by tests that require the collectionof cerebrospinal fluid (CSF). By investing in C2N, Eisai seeks to support efforts to advance blood-based
Aβ diagnostics that are accurate and affordable, providing new options for confirming the presence of Aβ.
“The field of highly accurate blood-based diagnostics is rapidly advancing and expanding,” said Keisuke
Naito, Global Alzheimer's Disease Officer, Senior Vice President, Eisai. “Given the expense and capacity
limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem’s growth. The
availability of more affordable and minimally invasive diagnostic tools helps support broad access for themanagement of Alzheimer’s disease.”
An estimated 6.7 million people in the U.S. are living with Alzheimer’s dementia.1 Clinical symptoms alone
cannot provide accurate diagnosis. Identifying patients through accurate and simple blood-based testing
may lead to more efficient diagnoses, expanded treatment opportunities and reduced medical and carecosts, thereby simplifying and accelerating earlier treatment, when appropriate. Importantly, blood-based
tests could also support improved care for people in underserved communities and areas where access toamyloid PET and CSF testing are not a viable option.
As a pioneer in the AD field and an hhceco company, Eisai is strongly committed to supporting thedevelopment of an environment that includes the blood-based diagnosis of AD. Using multiple approaches,
Eisai collaborates with several diagnostic companies and with local governments to expand the dementia
ecosystem. This investment and Eisai’s collaboration with C2N are examples of such activities, throughwhich we seek to provide and support solutions that can help relieve the anxieties of people living with AD,
their families and care partners.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Eisai Inc. (U.S.)
Libby Holman+ 1-201-753-1945
Libby_Holman@eisai.com[Notes to editors]
About C₂N Diagnostics, LLC

1.

C2N Diagnostics (“C2N”) is a specialty diagnostics company with a vision to bring Clarity Through Innovation ®. C2Nstrives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health.
C2N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decisionmaking to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency ofclinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare
researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important
epidemiologic studies to improve global public health.
C2N assays have been used in over 150 Alzheimer’s disease and other research studies throughout the U.S. and theworld. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that arechanging the trajectory of Alzheimer’s disease. C2N has ongoing collaborations with multi-national pharmaceutical andbiotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other nonprofits and consortiums. Over 15,000 Precivity™-related biomarker measures have been reported through peerreviewed publications, with many more manuscripts currently under review. For more information visit www.C2N.com.
1.

https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf